Learn
Compounded tirzepatide vs semaglutide: how the two medicines differ
By the Everlon founding team · · How we write and review health content
Compounded tirzepatide vs semaglutide is one of the first questions people ask about GLP-1 care. Here is how the two medicines differ, in plain terms. Which one fits you, if either, is a decision for a licensed provider who has reviewed your health history.
What each one acts on
- Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. It acts on the GLP-1 receptor.
- Tirzepatide acts on two receptors: the GIP receptor and the GLP-1 receptor.
How each one is taken
At Everlon, both are prescribed as a once-weekly injection under the skin. Your provider sets the starting dose and any changes to it.
Brand-name and compounded versions
FDA has approved brand-name versions of both medicines. Compounded versions are prepared by a licensed pharmacy for an individual patient. Compounded medications are not FDA-approved.
Who decides
Neither medicine is right for everyone. A licensed provider looks at your health history, your medicines and your goals, and decides whether either is appropriate. A prescription is never guaranteed, and at Everlon you're only charged if prescribed.
Sources
- FDA Approves New Medication for Chronic Weight Management — FDA, accessed 2026-10-21
- GLP-1 agonists — MedlinePlus, NIH, accessed 2026-10-21
- Compounding and the FDA: Questions and Answers — FDA, accessed 2026-10-21
Where to go next
Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.
Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.